Supernus Pharmaceuticals (SUPN) Competitors $33.87 +0.42 (+1.25%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SUPN vs. JAZZ, PRGO, PCRX, NKTR, OMER, ASMB, CPIX, LLY, JNJ, and ABBVShould you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV). These companies are all part of the "pharmaceuticals" industry. Supernus Pharmaceuticals vs. Its Competitors Jazz Pharmaceuticals Perrigo Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Jazz Pharmaceuticals (NASDAQ:JAZZ) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Do analysts prefer JAZZ or SUPN? Jazz Pharmaceuticals currently has a consensus target price of $181.64, suggesting a potential upside of 56.45%. Supernus Pharmaceuticals has a consensus target price of $39.00, suggesting a potential upside of 15.15%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jazz Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93Supernus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals and insiders hold more shares of JAZZ or SUPN? 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is JAZZ or SUPN more profitable? Jazz Pharmaceuticals has a net margin of 11.86% compared to Supernus Pharmaceuticals' net margin of 9.27%. Jazz Pharmaceuticals' return on equity of 26.62% beat Supernus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Jazz Pharmaceuticals11.86% 26.62% 9.14% Supernus Pharmaceuticals 9.27%12.23%9.17% Which has more risk and volatility, JAZZ or SUPN? Jazz Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Which has stronger earnings & valuation, JAZZ or SUPN? Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJazz Pharmaceuticals$4.06B1.73$560.12M$7.5015.48Supernus Pharmaceuticals$661.82M2.87$73.86M$1.1130.51 Does the media favor JAZZ or SUPN? In the previous week, Jazz Pharmaceuticals and Jazz Pharmaceuticals both had 9 articles in the media. Jazz Pharmaceuticals' average media sentiment score of 1.10 beat Supernus Pharmaceuticals' score of 1.06 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryJazz Pharmaceuticals beats Supernus Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SUPN vs. The Competition Export to ExcelMetricSupernus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.89B$3.89B$5.61B$9.56BDividend YieldN/A1.17%4.71%4.03%P/E Ratio30.497.5127.9020.10Price / Sales2.8712.14392.4667.55Price / Cash8.016.4836.3258.75Price / Book1.812.798.395.83Net Income$73.86M-$109.62M$3.25B$259.10M7 Day Performance2.73%-0.62%-1.61%-2.35%1 Month Performance7.45%10.03%9.08%9.75%1 Year Performance11.85%23.40%35.49%17.02% Supernus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SUPNSupernus Pharmaceuticals2.585 of 5 stars$33.87+1.3%$39.00+15.1%+9.3%$1.89B$661.82M30.49580News CoveragePositive NewsUpcoming EarningsAnalyst UpgradeGap UpJAZZJazz Pharmaceuticals4.8181 of 5 stars$112.65-0.2%$181.71+61.3%+4.9%$6.83B$4.07B6.712,800Positive NewsUpcoming EarningsPRGOPerrigo4.5303 of 5 stars$26.91-0.2%$33.00+22.6%+0.4%$3.71B$4.37B9.398,379Upcoming EarningsPCRXPacira BioSciences3.2513 of 5 stars$22.17+2.7%$26.44+19.3%+6.2%$999.42M$700.97M-9.72720NKTRNektar Therapeutics4.0778 of 5 stars$24.79-0.6%$88.33+256.3%+12.3%$309.43M$98.43M0.00220News CoveragePositive NewsUpcoming EarningsOMEROmeros3.7698 of 5 stars$3.64+8.3%$18.00+394.5%-26.2%$196.87MN/A0.00210Positive NewsUpcoming EarningsASMBAssembly Biosciences3.7987 of 5 stars$18.25-2.3%$33.00+80.8%+26.4%$142.67M$28.52M-2.93100Upcoming EarningsCPIXCumberland Pharmaceuticals0.8895 of 5 stars$3.50+8.7%N/A+144.1%$48.17M$37.87M-14.0080Upcoming EarningsLLYEli Lilly and Company4.9843 of 5 stars$762.22-1.2%$1,012.56+32.8%-5.5%$731.38B$45.04B56.0847,000Trending NewsJNJJohnson & Johnson4.8287 of 5 stars$164.38+0.4%$172.87+5.2%+6.0%$393.87B$88.82B16.37138,100Positive NewsAnalyst RevisionABBVAbbVie4.5691 of 5 stars$184.77-2.4%$211.29+14.4%+5.1%$334.31B$56.33B78.6255,000Trending NewsUpcoming Earnings Related Companies and Tools Related Companies JAZZ Alternatives PRGO Alternatives PCRX Alternatives NKTR Alternatives OMER Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SUPN) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shif...American Alternative | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
